The association of smoking with venous thrombosis in women

Summary

The evidence for an association between smoking and venous thrombosis (VT) is inconsistent, and its mediation pathways remain to be fully elucidated. A population-based, case-control study was conducted in a large, integrated healthcare system in Washington State, USA. Cases were women aged 18–90 years who experienced a validated incident deep-vein thrombosis or pulmonary embolism between January 1, 1995, and December 31, 2009. Controls were randomly selected from members of the healthcare system. Smoking status (current, former, never) was assessed from medical records review and, for a subset, also by telephone interview. Multivariable logistic regression was used to estimate odds ratios (OR) associated with smoking status. We identified 2,278 cases and 5,927 controls. Subjects comprised mostly postmenopausal white women with a mean age of 66 years and a current smoking prevalence of 10%. Compared to never-smokers, current and former smokers were at higher risk of VT (adjusted OR 1.21, 95% confidence interval [CI] 1.02–1.44 and OR 1.15, 95%CI 1.03–1.29, respectively). These associations were attenuated with further adjustment for potential mediators (cardiovascular disease, congestive heart failure, cancer, recent hospitalisations and physical activity): OR 1.02 (95%CI 0.83–1.25) and 0.95 (95%CI 0.83–1.08), respectively. In conclusion, the modestly increased risk of VT in women who are current or former smokers might be explained by the occurrence of smoking-related diseases and decreased physical activity. Our results do not support a direct biological effect of smoking on the risk of VT that is clinically relevant.

Note: Part of this work has been presented as a poster at the 58^th annual meeting of the Scientific & Standardization Committee of the ISTH in June 2012.

Keywords

Venous thrombosis - thromboembolism - women - smoking - epidemiology

• References

• 1 Roger VL, Go AS, Lloyd-Jones DM. et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
• 10 Centers for Disease Control and Prevention (CDC). Current cigarette smoking prevalence among working adults--United States, 2004-2010. Morb Mortal Wkly Rep 2011; 60: 1305-1309.
• 3 Ageno W, Becattini C, Brighton T. et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.
• 4 Pomp ER, Rosendaal FR, Doggen CJM. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008; 83: 97-102.
• 5 Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 2010; 121: 1896-1903.
• 6 Severinsen MT, Kristensen SR, Johnsen SP. et al. Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost 2009; 07: 1297-1303.
• 7 Wattanakit K, Lutsey PL, Bell EJ. et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis. Thromb Haemost 2012; 108: 508-515.
• 8 Lutsey PL, Virnig BA, Durham SB. et al. Correlates and consequences of venous thromboembolism: The Iowa Women’s Health Study. Am J Public Health 2010; 100: 1506-1513.
• 9 Enga KF, Braekkan SK, Hansen-Krone IJ. et al. Cigarette smoking and the risk of venous thromboembolism. the tromsø study. J Thromb Haemost 2012; 10: 2068-2074.
• 10 Smith NL, Heckbert SR, Lemaitre RN. et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. J Am Med Assoc 2004; 292: 1581-1587.
• 11 Psaty BM, Heckbert SR, Koepsell TD. et al. The risk of myocardial infarction associated with antihypertensive drug therapies. J Am Med Assoc 1995; 274: 620-625.
• 12 Psaty BM, Heckbert SR, Atkins D. et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333-1339.
• 13 Heckbert SR, Wiggins KL, Glazer NL. et al. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22: 538-544.
• 14 Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999; 08: 3-15.
• 15 Stata. Base Reference Manual (3 volumes). Stat Press; 2009
• 16 Koepsell T, Weiss N. Epidemiologic Methods: Studying the Occurrence of Illness. First edition Oxford University Press; 2003
• 17 Roos NP, Carrière KC, Friesen D. Factors influencing the frequency of visits by hypertensive patients to primary care physicians in Winnipeg. CMAJ 1998; 159: 777-83.
• 18 Starfield B, Weiner J, Mumford L. et al. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res 1991; 26: 53-74.
• 19 Lee KW, Lip GYH. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003; 163: 2368-2392.
• 20 Bazzano LA, He Muntner J. et al. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003; 138: 891-897.
• 21 Barua RS, Sy F, Srikanth S. et al. Acute cigarette smoke exposure reduces clot lysis--association between altered fibrin architecture and the response to t-PA. Thromb Res 2010; 126: 426-430.
• 22 Barua RS, Sy F, Srikanth S. et al. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler Thromb Vasc Biol 2010; 30: 75-79.
• 23 Bakhru A, Erlinger TP. Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey. PLoS Med 2005; 02: e160.
• 24 Caponnetto P, Russo C, Di Maria A. et al. Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study. Eur J Clin Invest 2011; 41: 616-626.
• 25 Rigotti NA, Pipe AL, Benowitz NL. et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221-229.
• 26 Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. Br Med J 2012; 344: e2856.
• 27 Caraballo RS, Giovino GA, Pechacek TF. et al. Factors associated with discrepancies between self-reports on cigarette smoking and measured serum cotinine levels among persons aged 17 years or older: Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2001; 153: 807-814.
• 28 Rosengren A, Fredén M, Hansson P-O. et al. Psychosocial factors and venous thromboembolism: a long-term follow-up study of Swedish men. J Thromb Haemost 2008; 06: 558-564.
• 29 Becattini C, Agnelli G, Schenone A. et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959-1967.